By PPN News Staff
The FDA approved olaparib (Lynparza, AstraZeneca) as an adjuvant treatment for adults with germline BRCA-mutated, high-risk, HER2-negative early breast cancer who have been treated with chemotherapy before or after surgery.
The approval was based on results of the OlympiA phase 3 trial, a randomized, double-blind, placebo–controlled, international study of 1,836 patients who were required to have completed at least six cycles of neoadjuvant or adjuvant chemotherapy